Table 3.
Bonferroni's t-test for AB reduction of osteogenic cells cultivated on the various BSM compared to the untreated control or EMD after 7 d
| Comparison | Diff of Means | t | p |
|---|---|---|---|
| control vs. BRE + EMD | 1544 | 14.0 | <0.001** |
| control vs. NBO + EMD | 1327 | 12.0 | <0.001** |
| control vs. BIM + EMD | 1206 | 10.9 | <0.001** |
| control vs. BOC + EMD | 1084 | 9.8 | <0.001** |
| control vs. CBM + EMD | 1002 | 9.1 | <0.001** |
| control vs. EMD | 758 | 6.9 | <0.001** |
| control vs. BIO + EMD | 400 | 3.6 | 0.015* |
| control vs. PGL + EMD | 54 | 0.4 | >1.0 |
| EMD vs. PGL + EMD | 812 | 7.0 | <0.001** |
| EMD vs. BRE + EMD | 786 | 6.8 | <0.001** |
| EMD vs. NBO + EMD | 569 | 4.9 | 0.001* |
| EMD vs. BIM + EMD | 448 | 3.8 | 0.009* |
| EMD vs. BIO + EMD | 358 | 3.1 | 0.048* |
| EMD vs. BOC + EMD | 326 | 2.8 | 0.085 |
| EMD vs. CBM + EMD | 244 | 2.1 | 0.352 |
(BIO = Bio-Oss®, NBO = NanoBone®, BRE = Bioresorb®, CBM = Cerasorb® M, PGL = PerioGlas®, BOC = Straumann® BoneCeramic, BIM = BONIT®matrix; t = probability; p = p-value; *significant, ** highly significant).